close

  
Filter options:

Freebase Commons Metaweb System Types /type

Object is not asserted on this topic.

Freebase Commons Common /common

  • Voriconazole (Mylan Pharmaceuticals), manufactured drug form of Voriconazole, 50mg/tablet voriconazole film coated tablet, NDC 0378-1626

Freebase Commons Business /business

Freebase Commons Medicine /medicine

Section name Section URI Prominent warning Highlight text Subject manufactured drug Section LOINC code
  • false
  • Voriconazole tablets are a triazole antifungal drug indicated for use in the treatment of: Invasive aspergillosis (1.1) Candidemia (nonneutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds (1.2) Esophageal candidiasis (1.3) Serious infections caused by Scedosporium apiospermum and Fusarium spp. including Fusarium solani , in patients intolerant of, or refractory to, other therapy (1.4)
  • -
  • 34067-9
  • false
  • Recommended Dosing Regimen (2)
  • -
  • 34068-7
  • false
  • Most frequent (all causalities, incidence ≥ 2%): visual disturbances, fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia, hallucinations (6) To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • -
  • 34084-4
  • false
  • -
  • -
  • 51945-4
  • false
  • Drug Interactions (5.1): review patient’s concomitant medications. Several drugs may significantly alter voriconazole concentrations. Voriconazole may alter PK or PD of several drugs (7) Hepatic Toxicity (5.2): serious hepatic reactions have been reported. Evaluate liver function tests at the start of and during the course of voriconazole therapy. Visual Disturbances (5.3): monitor visual function if treatment continues beyond 28 days Pregnancy Category D (5.4): do not administer to pregnant women Galactose Intolerance (5.5): do not administer to patients with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption Arrhythmias and QT Prolongation (5.6): administer with caution to patients with proarrhythmic conditions Dermatological Reactions (5.13): exfoliative cutaneous reactions and photosensitivity have been reported Skeletal Events (5.14): fluorosis and periostitis have been reported with long-term voriconazole therapy
  • -
  • 43685-7
  • false
  • Pregnant or nursing women: Voriconazole should not be used in pregnant or nursing women (8.1, 8.3) Pediatrics: safety/effectiveness in patients < 12 years has not been established (8.4) Hepatic impairment: use half the maintenance dose in patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) (2.7) Renal impairment: avoid intravenous administration in patients with moderate to severe renal impairment (creatinine clearance < 50 mL/min) (2.8)
  • -
  • 43684-0
  • false
  • -
  • -
  • 34088-5
  • false
  • -
  • -
  • 34076-0
  • false
  • Inhibitors and inducers of CYP3A4, CYP2C9 and CYP2C19 may alter voriconazole concentrations. Adjust the voriconazole dose and monitor for adverse events or lack of efficacy (4, 7) Voriconazole may increase the concentrations and activity of drugs that are CYP3A4, CYP2C9 and CYP2C19 substrates. Reduce doses of and monitor for lack of efficacy or adverse events associated with drugs that are substrates of these enzymes (4, 7)
  • -
  • 34073-7
  • false
  • -
  • -
  • 34069-5

Comments

Hide